Pregabalin In Partial Seizures: An Open-Label, International, Multicenter Add-On Therapy Trial.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.540 enrolled

Overview

To assess the clinical improvement (change in seizure frequency), safety and tolerability of patients with partial seizures following adjunctive therapy of pregabalin BID in addition to existing standard AEDs.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

540

Conditions

Seizures

Interventions

PregabalinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female subjects with a diagnosis of partial epilepsy. * 18 years and older. Exclusion Criteria: * Having a treatable cause of seizure. * Having a progressive neurological or systemic disorder

Locations (57)

Outcomes

Primary Outcomes

Reduction in seizure frequency.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

Bruges, Belgium

Pfizer Investigational Site

Brussels, Belgium

Pfizer Investigational Site

Duffel, Belgium

Pfizer Investigational Site

Ghent, Belgium

Pfizer Investigational Site

Leuven, Belgium

Pfizer Investigational Site

Liège, Belgium

Pfizer Investigational Site

Tielt, Belgium

Pfizer Investigational Site

Yvoir, Belgium

Pfizer Investigational Site

Helsinki, Finland

Pfizer Investigational Site

Kuopio, Finland

...and 47 more locations